Serina Therapeutics Files 8-K
Ticker: SER · Form: 8-K · Filed: Dec 11, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Regulation FD
TL;DR
Serina Therapeutics filed a routine 8-K, no new info.
AI Summary
Serina Therapeutics, Inc. filed an 8-K on December 11, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates Serina Therapeutics is meeting its reporting obligations with the SEC, but it does not disclose any new material events or financial information.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain any new material information that would indicate increased risk.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- December 11, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Serina Therapeutics, Inc.
In which state was Serina Therapeutics, Inc. incorporated?
Serina Therapeutics, Inc. was incorporated in Delaware.
What is the business address of Serina Therapeutics, Inc.?
The business address of Serina Therapeutics, Inc. is 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
What was the former name of Serina Therapeutics, Inc.?
The former name of Serina Therapeutics, Inc. was AgeX Therapeutics, Inc.
Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-12-11 06:11:29
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SER NYSE American Indic
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 28KB
- ex99-2.htm (EX-99.2) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 667KB
- ex99-1_002.jpg (GRAPHIC) — 546KB
- ex99-1_003.jpg (GRAPHIC) — 1734KB
- ex99-1_004.jpg (GRAPHIC) — 1047KB
- ex99-1_005.jpg (GRAPHIC) — 665KB
- ex99-1_006.jpg (GRAPHIC) — 964KB
- ex99-1_007.jpg (GRAPHIC) — 858KB
- ex99-1_008.jpg (GRAPHIC) — 1168KB
- ex99-1_009.jpg (GRAPHIC) — 1414KB
- ex99-1_010.jpg (GRAPHIC) — 1010KB
- ex99-1_011.jpg (GRAPHIC) — 933KB
- ex99-1_012.jpg (GRAPHIC) — 1006KB
- ex99-1_013.jpg (GRAPHIC) — 1008KB
- ex99-1_014.jpg (GRAPHIC) — 1022KB
- ex99-1_015.jpg (GRAPHIC) — 1138KB
- ex99-1_016.jpg (GRAPHIC) — 641KB
- ex99-1_017.jpg (GRAPHIC) — 1009KB
- ex99-1_018.jpg (GRAPHIC) — 1489KB
- ex99-1_019.jpg (GRAPHIC) — 1150KB
- ex99-1_020.jpg (GRAPHIC) — 1261KB
- ex99-1_021.jpg (GRAPHIC) — 1007KB
- ex99-1_022.jpg (GRAPHIC) — 861KB
- ex99-1_023.jpg (GRAPHIC) — 839KB
- ex99-1_024.jpg (GRAPHIC) — 651KB
- ex99-1_025.jpg (GRAPHIC) — 827KB
- ex99-1_026.jpg (GRAPHIC) — 985KB
- ex99-1_027.jpg (GRAPHIC) — 784KB
- ex99-1_028.jpg (GRAPHIC) — 1191KB
- ex99-1_029.jpg (GRAPHIC) — 767KB
- ex99-1_030.jpg (GRAPHIC) — 788KB
- ex99-1_031.jpg (GRAPHIC) — 1071KB
- ex99-1_032.jpg (GRAPHIC) — 548KB
- ex99-2_001.jpg (GRAPHIC) — 32KB
- 0001493152-24-049549.txt ( ) — 43004KB
- ser-20241211.xsd (EX-101.SCH) — 3KB
- ser-20241211_lab.xml (EX-101.LAB) — 33KB
- ser-20241211_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: December 11, 2024 By: /s/ Steve Ledger Chief Executive Officer